Distinct Functions of the Two Protein Tyrosine Phosphatase Domains of LAR (Leukocyte Common Antigen-Related) on Tyrosine Dephosphorylation of Insulin Receptor
Kazutake Tsujikawa,
Naoto Kawakami,
Yukiko Uchino,
Tomoko Ichijo,
Tatsuhiko Furukawa,
Haruo Saito and
Hiroshi Yamamoto
Department of Immunology (K.T., N.K., Y.U., T.I., H.Y.)
Graduate School of Pharmaceutical Sciences Osaka University
Osaka 565-0871, Japan
Department of Cancer Chemotherapy
(T.F.) Institute for Cancer Research Kagoshima University,
Faculty of Medicine Kagoshima 890-8520, Japan
Dana-Farber
Cancer Institute and Department of Biological Chemistry and Molecular
Pharmacology (H.S.) Harvard Medical School Boston,
Massachusetts 02115
 |
ABSTRACT
|
---|
Most receptor-like, transmembrane protein tyrosine
phosphatases (PTPases), such as CD45 and the leukocyte common
antigen-related (LAR) molecule, have two tandemly repeated PTPase
domains in the cytoplasmic segment. The role of each PTPase domain in
mediating PTPase activity remains unclear; however, it has been
proposed that PTPase activity is associated with only the first of the
two domains, PTPase domain 1, and the membrane-distal PTPase domain 2,
which has no catalytic activity, would regulate substrate specificity.
In this paper, we examine the function of each PTPase domain of LAR
in vivo using a potential physiological substrate, namely
insulin receptor, and LAR mutant proteins in which the conserved
cysteine residue was changed to a serine residue in the active site of
either or both PTPase domains. LAR associated with and preferentially
dephosphorylated the insulin receptor that was tyrosine phosphorylated
by insulin stimulation. Its association was mediated by PTPase domain
2, because the mutation of Cys-1813 to Ser in domain 2 resulted in
weakening of the association. The Cys-1522 to Ser mutant protein, which
is defective in the LAR PTPase domain 1 catalytic site, was tightly
associated with tyrosine-phosphorylated insulin receptor, but failed to
dephosphorylate it, indicating that LAR PTPase domain 1 is critical for
dephosphorylation of tyrosine-phosphorylated insulin receptor. This
hypothesis was further confirmed by using LAR mutants in which either
PTPase domain 1 or domain 2 was deleted. Moreover, the association of
the extracellular domains of both LAR and insulin receptor was
supported by using the LAR mutant protein without the two PTPase
domains. LAR was phosphorylated by insulin receptor tyrosine kinase and
autodephosphorylated by the catalytic activity of the PTPase domain 1.
These results indicate that each domain of LAR plays distinct
functional roles through phosphorylation and dephosphorylation in
vivo.
 |
INTRODUCTION
|
---|
Protein tyrosine phosphorylation, which is an important mechanism
for cellular signal transduction, is regulated by protein tyrosine
kinases (PTKs) and protein tyrosine phosphatases (PTPases) (1, 2).
Whereas the biological functions and regulatory mechanisms of
PTKs are well characterized, those of PTPases remain to be clarified.
PTPases contain at least one conserved catalytic domain (known as the
PTPase domain) that is composed of approximately 250 amino acids with a
conserved signature motif ([I/V]HCXAGXXR[S/T]G) around the active
site. The cysteine in the motif is the catalytic nucleophile that
mediates the dephosphorylation reaction through the formation of a
thio-phosphate bond (3). Mammalian PTPases that have been cloned to
date are structurally divided into two subgroups: intracellular PTPases
and transmembrane receptor-like PTPases (4, 5). All known intracellular
PTPases possess only one PTPase domain. Many of them, however, also
have accessory domains such as the Src homology 2 (SH2) domain, the
ezrin-like domain, or the Pro/Glu/Ser/Thr-rich (PEST) domain.
These accessory domains may regulate the activity, substrate
specificity, or subcellular localization of the intracellular PTPases
(6, 7).
In contrast, many receptor-like PTPases have two tandemly
repeated cytoplasmic PTPase domains. The membrane-proximal and
membrane-distal PTPase domains are called D1 (domain 1) and D2 (domain
2), respectively. Previous studies on the structure-function
relationships of the receptor-like PTPases indicated that: 1) D1 has
PTPase activity by itself; 2) the conserved cysteine residue in the
signature motif of D1 is essential for the PTPase activity; 3) the
three-dimensional structures of D1 and D2 are very similar; and 4) D2
has no or very little intrinsic catalytic activity (8, 9, 10, 11). These
results suggested that although D2 is structurally very similar to D1,
its function may be to regulate the catalytic activity or specificity
of D1.
Extracellular domains of receptor-like PTPases are composed of various
combinations of functional motifs such as the immunoglobulin-like (Ig)
repeat, the fibronectin type III (FnIII) repeat, and the carbonic
anhydrase-like domain, suggesting that the extracellular domain of
receptor-like PTPases may modulate PTPase activity by binding to
specific ligands. Specific ligands are, however, known for only a
handful of receptor-like PTPases: PTPß binds contactin and other
extracellular matrix molecules (12, 13, 14); PTP
, PTP
, and
PTPµ are homotypic receptors (15, 16, 17); and laminin-nidogen complex
binds to the fifth FnIII domain of human leukocyte common
antigen-related (LAR) molecule (18). Although effects of ligand binding
on PTPase activity are not known, it has been proposed that
homodimerization of receptor-like PTPases CD45 and PTP
may inhibit
their PTPase activities (19, 20). According to this model, PTPase
activity might be regulated by modulation (either promotion or
inhibition) of receptor dimerization induced by ligand binding.
However, the crystal structures of LAR and PTPµ do not lend
support to this model (11, 21).
Receptor-like PTPase LAR consists of non-covalently-bound subunits
designated the E (extracellular) subunit and the P (phosphatase)
subunit, generated by proteolytic cleavage of a single precursor
protein between the eighth FnIII domain and a transmembrane segment
(22, 23). The 150-kDa E subunit is composed of three Ig domains and
eight FnIII domains, whereas the 85-kDa P subunit has a short
extracellular domain, a transmembrane domain, and two tandemly repeated
PTPase domains (D1 and D2) in the cytoplasm. The E and P subunits of
LAR are connected by a noncovalent bond. There are several lines of
circumstantial evidence that implicate LAR PTPase in insulin receptor
signal transduction: 1) LAR is widely detected on a variety of
insulin-sensitive tissues such as liver, muscle, and adipocytes
(24, 25, 26); 2) LAR-deficient mice exhibit significantly lower levels of
plasma glucose as well as a reduced rate of hepatic glucose production
in the fasting state, and a significant resistance to
insulin-stimulated glucose disposal and suppression of hepatic glucose
output (27); 3) increased LAR PTPase activity toward the insulin
receptor is detected in subcutaneous adipose tissue of obese subjects
(28); 4) in in vitro experiments, the recombinant LAR PTPase
catalytic domain dephosphorylates a regulatory phosphorylation site
(Tyr-1150) in the insulin receptor ß-subunit (25); 5) in a rat
hepatoma cell line in which the expression of the LAR protein is
suppressed by antisense RNA, tyrosine phosphorylation of the insulin
receptor is significantly enhanced after insulin stimulation (29); and
6) LAR binds to and dephosphorylates tyrosine-phosphorylated insulin
receptor in Chinese hamster ovary cells that express human insulin
receptor and LAR molecules (CHO-hIR/LAR) as well as in a rat hepatoma
cell line (30, 31). These results suggest a negative regulatory role of
LAR in insulin signaling, and the dysregulation of LAR PTPase activity
might be a pathogenic factor in insulin-resistant diabetes.
The purpose of the current study is to clarify the functions of the two
PTPase domains of LAR in the regulation of insulin receptor tyrosine
dephosphorylation in vivo, using LAR mutants in which the
catalytic cysteine residue in D1 or D2 has been changed to serine, or
in which either D1 or D2 has been deleted. Using this approach, we
showed that the LAR D1 is responsible for insulin receptor
dephosphorylation, whereas the LAR D2 is mainly responsible for the
recognition of the phosphorylated insulin receptor. Moreover, the
association of extracellular domains of insulin receptor and LAR was
supported by using a LAR deletion mutant without both PTPase domains.
We found that LAR not only dephosphorylates insulin receptor but also
serves as a substrate of insulin receptor tyrosine kinase. Thus, the
extracellular domain and two PTPase domains of the receptor type PTPase
LAR have distinct functional roles in insulin receptor signaling.
 |
RESULTS
|
---|
Activated Insulin Receptor Is Tyrosine Dephosphorylated by LAR
Previous in vitro studies of the LAR PTPase
demonstrated that only the first PTPase domain (D1) has enzymatic
activity, whereas the second PTPase domain (D2) has no detectable
enzymatic activity but may modulate the activity of the PTPase D1.
However, these results were obtained using artificial substrates such
as phosphorylated oligopeptides. To investigate the functional
distinctions of the two PTPase domains under more physiological
conditions, we studied the in vivo regulation of one of its
likely physiological substrates, namely the insulin receptor (IR), by
LAR.
Initially, COS-7 cells were cotransfected with IR, together with the
full-length LAR wild type (LAR WT), a LAR mutant that harbors the
Cys-1522 to Ser substitution at the catalytic center of PTPase D1 (this
mutation will be abbreviated as LAR D1CS), or the empty vector. The
Cys-1522 to Ser mutation completely abolishes the in vitro
LAR PTPase activity using artificial substrates. NP40 lysates were
prepared from the transfected cells at various times after the
stimulation with 100 nM insulin, and the
tyrosine-phosphorylated proteins were detected by immunoblotting with
antiphosphotyrosine monoclonal antibody (mAb) 4G10 (Fig. 1
). A 95-kDa protein was prominently
tyrosine phosphorylated 1 min after the insulin stimulation, and the
tyrosine phosphorylation levels remained almost constant for 15 min
after the insulin stimulation. When the same blot was reprobed with
anti-IR ß-subunit antiserum, a 95-kDa protein band was detected (data
not shown), indicating that the 95-kDa tyrosine-phosphorylated band is
the insulin receptor.
The tyrosine-phosphorylated IR levels in LAR WT transfectants were
markedly lower than those in LAR D1CS transfectants and mock
transfectants at any time after the insulin stimulation. These results
indicate that the IR ß-subunit is a possible substrate of the LAR
PTPase and that the LAR PTPase D1CS mutant does not have catalytic
activity in vivo.
In the LAR D1CS transfectants, several additional proteins were also
tyrosine phosphorylated prominently, even in the absence of insulin
stimulation. There are two possible explanations for the increased
tyrosine phosphorylation of these proteins: 1) the IR tyrosine kinase
remains in the active state, due to the inability of LAR D1CS to
dephosphorylate, and continues to tyrosine phosphorylate other
proteins; or 2) these phosphorylated proteins are also substrates of
LAR. To determine which of these two explanations was correct, COS-7
cells were cotransfected with LAR D1CS and IR and stimulated with
insulin for 1 min, and NP40 cell lysates were prepared. LAR in the
lysates was immunoprecipitated with anti-LAR E subunit mAbs (a mixture
of 11.1A, 75.3A, and 71.2E), and the precipitates were immunoblotted
with the antiphosphotyrosine mAb 4G10. Cys-to-Ser mutants of several
PTPases are known to tightly bind their specific
tyrosine-phosphorylated substrates without dephosphorylating them
(32, 33, 34, 35). By analogy, it might be expected that LAR D1CS would
tightly bind the tyrosine-phosphorylated form of its physiological
substrates. As shown in Fig. 2B
, only
three bands of phosphorylated proteins, at 200 kDa, 95 kDa, and 85 kDa,
were detected in LAR D1CS immunoprecipitates. The 95-kDa protein is IR,
because it was detected with anti-IR antiserum (Fig. 2A
). The other two
bands are the LAR precursor and the LAR P subunit (see below). These
results favor the first explanation.
The LAR P Subunit Is Tyrosine Phosphorylated by Insulin
Stimulation
LAR is synthesized as an approximately 200-kDa precursor protein
that is cleaved by an endogenous protease into two subunits, the
150-kDa E subunit and the 85-kDa P subunit (23). The LAR P subunit
contains the transmembrane segment and the entire cytoplasmic domain.
Because the 200-kDa and 85-kDa tyrosine-phosphorylated proteins in LAR
D1CS immunoprecipitated with anti-LAR E subunit mAbs (Fig. 2B
) are
about the same size as the LAR precursor and P subunit, respectively,
we examined whether LAR is tyrosine phosphorylated. To this end, we
generated a mAb (YU1) that recognizes the LAR P subunit by immunizing
mice with a glutathione-S-transferase (GST)-LAR cytoplasmic
domain fusion protein. The same filter as shown in Fig. 2B
was reprobed
with the anti-LAR P subunit mAb YU1. As shown in Fig. 2C
, 200-kDa and
85-kDa protein bands, which correspond precisely to the
tyrosine-phosphorylated proteins, were detected by YU1, indicating that
the 200-kDa and 85-kDa tyrosine-phosphorylated proteins are the LAR
precursor protein and the LAR P subunit, respectively.
LAR PTPase D2 Is Important for Recognition of the Insulin
Receptor
To examine whether the LAR D1 and D2 play distinct roles in the
LAR-IR interaction, we used three LAR mutants; namely LAR D1CS, LAR
D2CS (Cys-1813 to Ser mutation in D2), and LAR D1D2CS (a mutant with
both Cys-1522 to Ser in D1 and Cys-1813 to Ser in D2). These LAR
mutants, or LAR WT, were individually transfected together with IR.
Cell lysates were prepared 1 min after insulin stimulation, and LAR was
immunoprecipitated with anti-LAR E subunit mAbs. Immunoblots with the
antiphosphotyrosine mAb 4G10, the anti-LAR P subunit mAb YU1, and the
anti-IR antiserum are shown in Fig. 3
, and the relative intensities of bands detected with the
antiphosphotyrosine mAb 4G10 were analyzed by densitometry (Fig. 4
). Tyrosine-phosphorylated insulin
receptor was efficiently coimmunoprecipitated with LAR D1CS, moderately
coimmunoprecipitated with LAR WT and LAR D1D2CS, but only negligibly
coimmunoprecipitated with LAR D2CS (Fig. 3A
). Interestingly, the
immunoblotting with anti-IR antiserum indicated that IR was present in
the LAR WT and LAR D1CS immunoprecipitates at about the same level, but
there was very little in the LAR D2CS or LAR D1D2CS immunoprecipitates
(Fig. 3B
), even though the levels of immunoprecipitated LAR (Fig. 3C
)
and the expression levels of insulin receptor (Fig. 3E
) in these
transfected cells were very similar. These results indicate that the
cysteine residue in LAR D2 is important for the binding to the insulin
receptor and that such D2-mediated binding is needed for efficient
tyrosine dephosphorylation of the IR ß-subunit by the LAR D1 domain.
Consistent with this interpretation, the total tyrosine phosphorylation
level of IR in cell lysates of the LAR WT transfectant was
significantly lower than those of LAR D1CS, D2CS, and D1D2CS (Figs. 1D
and 4B
), indicating that both D1 and D2 are important for IR
dephosphorylation. Interestingly, the tyrosine phosphorylation levels
of the LAR P subunit were significantly increased in the LAR D1CS and
LAR D1D2CS transfectants compared with the LAR WT or LAR D2CS
transfectant (Figs. 3A
and 4A
), suggesting that the phosphorylated
tyrosine residue(s) of LAR P subunit is/are dephosphorylated mainly by
the catalytic activity of LAR PTPase D1.

View larger version (14K):
[in this window]
[in a new window]
|
Figure 4. Densitometric Analysis of Tyrosine Phosphorylation
Levels of Insulin Receptor and LAR P Subunit
The immunoblots with antiphosphotyrosine mAb shown in Fig. 3 , panels A
and D, were scanned by a densitometer, and the relative intensity of
tyrosine phosphorylation levels of (A) insulin receptor associated with
LAR (open bar) and LAR P-subunit (filled
bar), and (B) insulin receptor in cell lysates were analyzed by
an NIH image software.
|
|
To further clarify the distinct functions of LAR D1 and D2, we
constructed three LAR deletion mutants, i.e. LAR
D1 and
LAR
D2 (mutants lacking D1 and D2, respectively) and LAR
PTPase
(a mutant lacking both D1 and D2). These LAR deletion mutants, or LAR
CS, were individually transfected into COS-7 cells together with IR as
described above. LAR was immunoprecipitated with anti-LAR E subunit
mAbs from the cell lysates prepared 1 min after insulin stimulation.
Figure 5A
shows the immunoblot with the
antiphosphotyrosine mAb PY20 conjugated with horseradish peroxidase.
Tyrosine-phosphorylated IR was most prominently coimmunoprecipitated
with LAR D1CS, was moderately so with LAR
PTPase and LAR
D1, and
was only negligibly so with LAR
D2. When the same blot was reprobed
with anti-LAR E subunit mAbs, almost the same intensities of 150-kDa
bands were detected in transfectants of LAR D1CS,
D2, and
PTPase,
but the intensity in LAR
D1 was much weaker (Fig. 5B
). However, the
obvious association of LAR
D1 with tyrosine-phosphorylated IR was
detected in spite of its weak expression, indicating that LAR D2 plays
an important role in the recognition of tyrosine-phosphorylated IR.
Interestingly, the binding of tyrosine-phosphorylated IR to LAR
PTPase, which has no PTPase domains, was also detectable, suggesting
the possibility of association between the extracellular domains of
both LAR and IR. When the same blot was reprobed with anti-LAR P
subunit mAb YU1, 85-kDa, 53-kDa, 51-kDa, and 22-kDa bands were detected
in transfectants of LAR DCS,
D2,
D1, and
PTPase, respectively
(Fig. 5C
). These bands, with the exception of the 53-kDa band of LAR
D2, completely corresponded to the bands detected with an
antiphosphotyrosine mAb in Fig. 5A
, indicating that tyrosine residue(s)
existing between the transmembrane domain and the PTPase domain 1 of
LAR were tyrosine phosphorylated by IR. An in vitro PTPase
assay indicated that LAR
D2 immunoprecipitated from COS-7
transfectants with anti-LAR E subunit mAbs had obvious PTPase activity,
but LAR
D1 or LAR
PTPase immunoprecipitates had no activity (data
not shown). Therefore, we supposed that since LAR
D2 could bind to
tyrosine-phosphorylated IR and promptly dephosphorylated the IR and
tyrosine-phosphorylated LAR, only a weak band of
tyrosine-phosphorylated IR was detected.
The LAR P Subunit Is a Substrate for the Insulin Receptor Tyrosine
Kinase
The LAR P subunit is tyrosine phosphorylated after insulin
stimulation in transfected COS-7 cells. To examine whether LAR is
phosphorylated by the insulin receptor tyrosine kinase, wild-type and
kinase-inactive mutant insulin receptor constructs, in which Lys-1013
at the ATP binding site is mutated to Met, were used for transfection
assays. Expression plasmids for the wild-type insulin receptor (IR WT)
or the kinase-inactive mutant insulin receptor (IR MT) were
cotransfected together with LAR D1CS. One minute after insulin
stimulation, cell lysates were prepared and LAR was immunoprecipitated
with anti-LAR E subunit mAbs, followed by immunoblotting with
antiphosphotyrosine mAb 4G10. As shown in Fig. 6A
, the LAR P subunit as well as the
coprecipitated IR ß-subunit were tyrosine phosphorylated in cells
transfected with the IR WT but not in those transfected with the IR MT.
In these experiments, expression levels of both IR and LAR were
comparable between the two transfected cells (data not shown). These
results thus indicate that the LAR P subunit is a substrate of the
insulin receptor tyrosine kinase. Moreover, when the same blot was
reprobed with the anti-IR antiserum, IR was detected in both IR WT and
IR MT transfectants (Fig. 6B
), indicating that part of LAR-IR
association is independent of the IR phosphorylation state.
 |
DISCUSSION
|
---|
Most receptor-like PTPases such as LAR have two tandemly repeated
PTPase domains in the cytoplasmic segment, although the precise
function and the regulatory mechanism of each PTPase domain have not
been clarified. Previous studies indicated that the membrane-proximal
PTPase D1 of LAR has catalytic activity by itself, since the cysteine
to serine-substituted mutation at the catalytic center of D1 completely
eliminated the PTPase activity (9). In contrast, the membrane-distal
PTPase D2 has no detectable enzymatic activity, even though its
structure is strikingly similar to D1 (11). Removal of LAR PTPase D2,
however, altered the specificity to artificial in vitro
substrates, myelin basic protein, and the synthetic peptide Raytide,
suggesting that the PTPase D2 might regulate substrate specificity. To
clarify the precise function and the regulatory mechanism of each
PTPase domain of LAR in vivo, however, studies using a
physiological substrate of LAR are essential.
In this study, our criteria for a physiological substrate of LAR were
as follows: 1) a LAR substrate is dephosphorylated more efficiently by
LAR PTPase than other tyrosine-phosphorylated proteins, and 2) a
tyrosine-phosphorylated substrate of LAR has a high affinity to LAR
PTPase D1. We demonstrated preferential dephosphorylation of
tyrosine-phosphorylated insulin receptor by LAR PTPase and a specific
association of LAR D1CS mutant with the tyrosine-phosphorylated insulin
receptor. Recently, Ahmad et al. (30, 31) also reported a
physical association of rat LAR and the human insulin receptor
overexpressed in CHO cells. The association seems to increase in
accordance with the tyrosine phosphorylation of insulin receptor. These
results indicate that the insulin receptor is a likely physiological
substrate of LAR. Based on these findings, our present study has
further clarified distinct functions of the two PTPase domains of LAR
for the insulin receptor by various kinds of LAR mutants in
vivo.
In cotransfection experiments, we found that LAR WT efficiently
dephosphorylated the insulin receptor activated by insulin stimulation.
On the other hand, the tyrosine-phosphorylated insulin receptor was
coprecipitated with LAR D1CS, a substrate trapping mutant of LAR,
indicating the tight association of these two molecules. These results
support that LAR PTPase D1 is involved in a catalytic process, and that
Cys-1522 located at the catalytic center of the PTPase D1 is critical
for its catalytic activity in vitro (9) as well as in
vivo. In the same way, it might be expected that if LAR PTPase D2
has a catalytic effect on the phosphorylated insulin receptor, both LAR
D2CS and LAR D1D2CS mutants could efficiently trap the
tyrosine-phosphorylated insulin receptor as well. However, neither LAR
D2CS nor LAR D1D2CS showed a marked binding to the phosphorylated
insulin receptor as was seen in LAR D1CS, suggesting that LAR PTPase D2
does not catalyze the dephosphorylation of the insulin receptor.
Interestingly, the association of the insulin receptor to LAR
constructs that have no mutation in the domain 2, such as LAR WT and
LAR D1CS, is significantly weakened by the introduction of Cys to
Ser-substituted mutation in LAR D2. In contrast, LAR
D1 that has
only a wild-type PTPase domain 2 in the cytoplasm showed obvious
binding to the phosphorylated insulin receptor. These results indicate
that LAR PTPase D2 is important for the recognition of a substrate, the
insulin receptor, and that Cys-1813 in the domain is essential for
recognition in vivo.
Ahmad and Goldstein (31) have reported that LAR is associated with the
insulin receptor and that the association is enhanced by insulin
stimulation. We also confirmed the physical association between LAR and
the insulin receptor in transfected COS-7 cells. However, LAR
PTPase
was found to be associated with the insulin receptor in spite of the
complete absence of LAR PTPase domains. These results indicated that
not only the PTPase domains of LAR but also its extracellular domain
are involved in the association with the insulin receptor.
LAR undergoes proteolytic processing when cells are grown to a high
density or in response to increases in cytoplasmic Ca levels and
protein kinase C activity (23). Aicher et al. (36) have
reported that the processing of LAR is detected 5 min and 40 min after
calcium ionophore stimulation in A431 and Hela cells, respectively. In
our transfection assay of COS-7 cells, we could hardly detect the shed
LAR in the culture media at 1 min, and we could detect it only slightly
at 5 min after insulin stimulation (data not shown). Therefore, the
processing of the LAR extracellular domain would not affect the
interpretation of the results from immunoprecipitation assays with
anti-LAR E subunit mAbs in this study.
LAR was tyrosine phosphorylated by tyrosine kinase activity of insulin
receptor in response to insulin stimulation and rapidly
autodephosphorylated in vivo. Some tyrosine phosphatases,
such as PTP1C (37), PTP
(38), and PTPase 1B (39), are also known to
be tyrosine phosphorylated by the insulin receptor tyrosine kinase. The
phosphorylation of PTP1C increases its PTPase activity, and that of
PTPase 1B is necessary for its interaction with insulin receptor. The
tyrosine phosphorylation of PTP
leads to a reduction of the insulin
receptor signaling (the activation of an endogenous kinases, such as
Src, and the binding of Grb2) (40). The tyrosine phosphorylation sites
in LAR, the functional significance of the phosphorylation, and the
understanding of the change, if there is any, in the catalytic activity
caused by the phosphorylation are unclear. Nonetheless, the
phosphorylation and autodephosphorylation of LAR tyrosine residues are
likely to play important functions in the regulatory mechanism of
insulin-receptor signal transduction.
Based on the results of this study, we propose a new model of the
tyrosine dephosphorylation mechanism of insulin receptor by LAR PTPase.
LAR weakly associates with the insulin receptor at the steady state via
the LAR extracellular domain. After insulin binding, insulin receptor
tyrosine kinase induces autophosphorylation, leading to increased
tyrosine kinase activity. The activated insulin receptor tyrosine
kinase phosphorylates its substrates, including LAR. The tyrosine
phosphorylation of LAR might induce the conformational change of the
PTPases D1 and/or D2, resulting in a tighter association via LAR PTPase
domain 2, and then dephosphorylating phosphotyrosine residues of the
insulin receptor by the catalytic activity of the PTPase D1. A
phosphorylated tyrosine residue(s) of LAR is also dephosphorylated by
the catalytic activity of the PTPase D1 to return to the preactivation
state.
Insulin receptor signaling is important for both cell growth and
glucose metabolism. Molecular links between LAR and phosphorylated
tyrosine residues of the insulin receptor are suggested. However, the
elaborate regulatory mechanism by the two PTPase domains of LAR must
still be clarified, perhaps using both the insulin receptor mutants
with substitutions of tyrosine resides and various LAR mutants.
 |
MATERIALS AND METHODS
|
---|
Plasmid Constructions
The LAR expression vectors (WT, D1CS, D2CS, and D1D2CS) were
constructed by inserting LAR and its Cys to Ser mutants described
previously (9) into a modified version of the pcDL-SR
296 expression
plasmid termed pSP65-SR
2 (41). pSP65-SR
2-LAR
PTPase (amino
acids 11,343) and pSP65-SR
2-LAR
D2 (amino acids 11,590)
deletion mutants were constructed by removing appropriate restriction
fragments from pSP65-SR
2-LAR WT. A cDNA sequence corresponding to
LAR PTPase domain 2 (amino acids 1,6331,881) with appropriate
restriction sites for subcloning were generated by PCR and inserted
in-frame into the pSP65-SR
2-LAR
PTPase to construct LAR
D1.
Their nucleotide sequences were confirmed by DNA sequencing. The
numbering of LAR amino acid residues is in accordance with Streuli
et al. (22). Human insulin receptor expression vectors,
pSR
-human insulin receptor (pSR
-IR) and pSR
-IR K1030M, in
which Lys-1030 at the ATP binding site of the insulin receptor is
changed to Met, were kindly provided by Dr. Ebina.
Cell Culture and Transfections
COS-7 cells, obtained from the Human Science Research Resources
Bank (Osaka, Japan), were grown at 37 C in a 5%
CO2 atmosphere in RPMI 1640 medium (Nissui
Pharmaceutical, Tokyo, Japan) supplemented with 10%
heat-inactivated FCS (Life Technologies, Inc.,
Gaithersburg, MD) and 10 mg/ml kanamycin. Cells were cotransfected with
5 µg of pSP65-SR
2-LAR and 1 µg of pSR
-IR by the
diethylaminoethyl (DEAE)-dextran method (42). After incubation for
48 h, the transfected cells were starved for 16 h in
serum-free RPMI 1640 medium and then stimulated with 100 nM
insulin for the indicated times. After washing with ice-cold PBS
containing 1 mM sodium vanadate, 5 mM NaF, 5
mM sodium pyrophosphate, and 5 mM EDTA, the
cells were lysed on ice in 1 ml of ice-cold lysis buffer (1% NP40, 150
mM NaCl, 50 mM Tris, pH 7.4, 5 mM
EDTA, 10 mM iodoacetamide, 10 mM NaF, 10
mM sodium pyrophosphate, 0.4 mM sodium
vanadate, 0.1 mM phenylarsine oxide, 1 mM
phenylmethylsulfonyl fluoride, and 1 mM benzamidine). The
cell lysates were centrifuged in a microcentrifuge to remove insoluble
materials before immunoprecipitation and immunoblotting.
Immunoprecipitation and Immunoblotting
Cell lysates were precleared with approximately 15 µg
isotype-matched control mAbs (Transduction Laboratories, Inc., Lexington, KY) and 20 µl Gamma-bind (Amersham Pharmacia Biotech, Arlington Heights, IL) for more than 2 h
at 4 C. For immunoprecipitation, cell lysates were incubated with 15
µg monoclonal anti-LAR mAbs (1:1 mixture of 11.1A and 75.3A) (23) for
1 h at 4 C, and then with 20 µl Gamma-bind for an additional
1 h at 4 C. After washing twice with 1 ml lysis buffer as
described above and once with 1 ml PBS with 10 mM NaF, 10
mM sodium pyrophosphate, 0.4 mM sodium
vanadate, and 0.1 mM phenylarsine oxide, immunoprecipitates
were resolved by SDS-PAGE. Proteins in immunoprecipitates and cell
lysates were transferred from a SDS-polyacrylamide gel to a
nitrocellulose membrane (Schleicher & Schuell, Inc.,
Keene, NH), blocked with 3% BSA in TBS-T (20 mM Tris-HCl
pH 8.0, 137 mM NaCl, and 0.1% Tween 20) and incubated with
primary mAbs at room temperature for 1 h, followed by washing
three times with TBS-T. To detect antibody binding, horseradish
peroxidase-conjugated antimouse IgG or horseradish
peroxidase-conjugated antirabbit IgG (Transduction Laboratories, Inc.) diluted in TBS-T was incubated at room temperature for
1 h. After washing in TBS-T three times, bound horseradish
peroxidase conjugates were visualized with enhanced chemiluminescent
reagent (Wako Pure Chemical Industries, Ltd.,
Osaka, Japan). The antibodies used were antiphosphotyrosine mAb 4G10
(Upstate Biotechnology, Inc., Lake Placid, NY),
antiinsulin receptor ß-subunit (Transduction Laboratories, Inc.), anti-LAR E subunit mAbs (1:1:1 mixture of 75.3A, 11.1A,
and 71.2E) (23), and anti-LAR P subunit mAb (YU1). For the blot of
immunoprecipitates from lysates of COS-7 cells cotransfected with LAR
deletion mutants and IR, we used antiphosphotyrosine mAb PY20
conjugated with horseradish peroxidase (Santa Cruz Biotechnology, Inc., Santa Cruz, CA).
Preparation of Antihuman LAR P Subunit mAb (YU1)
The anti-LAR P subunit mAb YU1 was generated by immunization
with a recombinant glutathione S-transferase fusion protein
with the LAR P subunit beyond transmembrane segment expressed in a
pGEX-2T vector (Amersham Pharmacia Biotech).
 |
ACKNOWLEDGMENTS
|
---|
We thank Dr. Michel Streuli (Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA) for providing human LAR expression
vectors and anti-LAR monoclonal antibodies, and Dr. Yousuke Ebina (the
Department of Enzyme Genetics, the University of Tokushima, Tokushima,
Japan) for human insulin receptor expression vectors. We also
appreciate Dr. Pauline OGray (Dana-Farber Cancer Institute, Harvard
Medical School) and Dr. Masato Kasuga (the Second Department of
Internal Medicine, Kobe University School of Medicine, Kobe, Japan) for
helpful advice.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Dr. Kazutake Tsujikawa, Department of Immunology, Graduate School of Pharmaceutical Sciences, Osaka University, 16 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail:
tujikawa{at}phs osaka-u.ac.jp.
This work was supported by Grant-in-Aid for Scientific Research from
the Ministry of Education, and a grant from Fuso Pharmaceutical
Industries, Ltd.
Received for publication January 19, 2000.
Revision received September 25, 2000.
Accepted for publication October 13, 2000.
 |
REFERENCES
|
---|
-
Denu JM, Stuckey JA, Saper MA, Dixon JE 1996 Form and
function in protein dephosphorylation. Cell 87:361364[Medline]
-
Tonks NK, Neel BG 1996 From form to function: signaling by
protein tyrosine phosphatases. Cell 87:365368[Medline]
-
Pot DA, Dixon JE 1992 Active site labeling of a receptor-like
protein tyrosine phosphatase. J Biol Chem 267:140143[Abstract/Free Full Text]
-
Walton KM, Dixon JE 1993 Protein tyrosine phosphatases. Annu
Rev Biochem 62:101120[CrossRef][Medline]
-
Neel BG, Tonks NK 1997 Protein tyrosine phosphatases in
signal transduction. Curr Opin Cell Biol 9:193204[CrossRef][Medline]
-
Lechleider RJ, Sugimoto S, Bennett AM, Kashishian AS, Cooper
JA, Shoelson SE, Walsh CT, Neel BG 1993 Activation of the
SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site,
phosphotyrosine 1009, on the human platelet-derived growth factor
receptor. J Biol Chem 268:2147821481[Abstract/Free Full Text]
-
Frangioni JV, Beahm PH, Shifrin V, Jost CA, Neel BG 1992 The
nontransmembrane tyrosine phosphatase PTP-1B localizes to the
endoplasmic reticulum via its 35 amino acid C-terminal sequence. Cell 68:545560[Medline]
-
Krueger NX, Streuli M, Saito H 1990 Structural diversity and
evolution of human receptor-like protein tyrosine phosphatases. EMBO J 9:32413252[Abstract]
-
Streuli M, Krueger NX, Thai T, Tang M Saito H 1990 Distinct
functional roles of the two intracellular phosphatase like domains of
the receptor-linked protein tyrosine phosphatases LCA and LAR. EMBO J 9:23992407[Abstract]
-
Wang Y, Pallen CJ 1991 The receptor-like protein tyrosine
phosphatase HPTP alpha has two active catalytic domains with distinct
substrate specificities. EMBO J 10:32313237[Abstract]
-
Nam HJ, Poy F, Krueger NX, Saito H, Frederick CA 1999 Crystal
structure of the tandem phosphatase domains of RPTP LAR. Cell 97:449457[Medline]
-
Peles E, Nativ M, Campbell PL, Sakurai T, Martinez R, Lev S,
Clary DO, Schilling J, Barnea G, Plowman GD 1995 The carbonic anhydrase
domain of receptor tyrosine phosphatase ß is a functional ligand for
the axonal cell recognition molecule contactin. Cell 82:251260[Medline]
-
Maeda N, Noda M 1998 Involvement of receptor-like protein
tyrosine phosphatase
/RPTPß and its ligand
pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) in
neuronal migration. J Cell Biol 142:203216[Abstract/Free Full Text]
-
Peles E, Schlessinger J, Grumet M 1998 The carbonic anhydrase
domain of receptor tyrosine phosphatase ß is a functional ligand for
the axonal cell recognition molecule contactin. Trends Biochem Sci 23:121124[CrossRef][Medline]
-
Sap J, Jiang YP, Friedlander D, Grumet M, Schlessinger J 1994 Receptor tyrosine phosphatase R-PTP-
mediates homophilic binding.
Mol Cell Biol 14:19[Abstract]
-
Cheng J, Wu K, Armanini M, ORourke N, Dowbenko D, Lasky LA 1997 A novel protein-tyrosine phosphatase related to the homotypically
adhering
and µ receptors. J Biol Chem 272:72647277[Abstract/Free Full Text]
-
Brady-Kalnay SM, Flint AJ, Tonks NK 1993 Homophilic binding of
PTP µ, a receptor-type protein tyrosine phosphatase, can mediate
cell-cell aggregation. J Cell Biol 122:961972[Abstract]
-
OGrady P, Thai TC, Saito H 1998 The laminin-nidogen complex
is a ligand for a specific splice isoform of the transmembrane protein
tyrosine phosphatase LAR. J Cell Biol 141:16751684[Abstract/Free Full Text]
-
Desai DM, Sap J, Schlessinger J, Weiss A 1993 Ligand-mediated
negative regulation of a chimeric transmembrane receptor tyrosine
phosphatase. Cell 73:541554[Medline]
-
Bilwes AM, den-Hertog J, Hunter T, Noel JP 1996 Structural
basis for inhibition of receptor protein-tyrosine phosphatase-
by
dimerization. Nature 382:555559[CrossRef][Medline]
-
Hoffmann KM, Tonks NK, Barford D 1997 The crystal structure of
domain 1 of receptor protein-tyrosine phosphatase µ. J Biol Chem 272:2750527508[Abstract/Free Full Text]
-
Streuli M, Krueger NX, Hall LR, Schlossman SF, Saito H 1988 A
new member of the immunoglobulin superfamily that has a cytoplasmic
region homologous to the leukocyte common antigen. J Exp Med 168:15231530[Abstract]
-
Streuli M, Krueger NX, Ariniello PD, Tang M, Munro JM,
Blattler WA, Adler DA, Disteche CM, Saito H 1992 Expression of the
receptor-linked protein tyrosine phosphatase LAR: proteolytic cleavage
and shedding of the CAM-like extracellular region. EMBO J 11:897907[Abstract]
-
Serra PC, Kedersha NL, Fazikas L, Medley Q, Debant A, Streuli
M 1995 The LAR transmembrane protein tyrosine phosphatase and a
coiled-coil LAR-interacting protein co-localize at focal adhesions.
EMBO J 14:28272838[Abstract]
-
Hashimoto N, Feener EP, Zhang WR, Goldstein BJ 1992 Insulin
receptor protein-tyrosine phosphatases. Leukocyte common
antigen-related phosphatase rapidly deactivates the insulin receptor
kinase by preferential dephosphorylation of the receptor regulatory
domain. J Biol Chem 267:1381113814[Abstract/Free Full Text]
-
Zhang WR, Hashimoto N, Ahmad F, Ding W, Goldstein BJ 1994 Molecular cloning and expression of a unique receptor-like
protein-tyrosine-phosphatase in the leucocyte-common-antigen-related
phosphate family. Biochem J 302:3947[Medline]
-
Ren JM, Li PM, Zhang WR, Sweet LJ, Cline G, Shulman GI,
Livingston JN, Goldstein BJ 1998 Transgenic mice deficient in the LAR
protein-tyrosine phosphatase exhibit profound defects in glucose
homeostasis. Diabetes 47:493497[Abstract]
-
Ahmad F, Considine RV, Goldstein BJ 1995 Increased abundance
of the receptor-type protein-tyrosine phosphatase LAR accounts for the
elevated insulin receptor xdephosphorylating activity in adipose tissue
of obese human subjects. J Clin Invest 95:28062812[Medline]
-
Kulas DT, Zhang WR, Goldstein BJ, Furlanetto RW, Mooney RA 1995 Insulin receptor signaling is augmented by antisense inhibition of
the protein tyrosine phosphatase LAR. J Biol Chem 6:24352438[CrossRef]
-
Zhang WR, Li PM, Oswald MA, Goldstein BJ 1996 Modulation of
insulin signal transduction by eutopic overexpression of the
receptor-type protein-tyrosine phosphatase LAR. Mol Endocrinol 10:575584[Abstract]
-
Ahmad F, Goldstein BJ 1997 Functional association between the
insulin receptor and the transmembrane protein-tyrosine phosphatase LAR
in intact cells. J Biol Chem 272:448457[Abstract/Free Full Text]
-
Furukawa T, Itoh M, Krueger NX, Streuli M, Saito H 1994 Specific interaction of the CD45 protein-tyrosine phosphatase with
tyrosine-phosphorylated CD3
chain. Proc Natl Acad Sci USA 91:1092810932[Abstract/Free Full Text]
-
Wurgler-Murphy SM, Maeda T, Witten EA, Saito H 1997 Regulation of the Saccharomyces cerevisiae HOG1
mitogen-activated protein kinase by the PTP2 and PTP3 protein tyrosine
phosphatases. Mol Cell Biol 17:12891297[Abstract]
-
Sun H, Chales CH, Lau LF, Tonks NK 1993 MKP-1 (3CH134), an
immediate early gene product, is a dual specificity phosphatase that
dephosphorylates MAP kinase in vivo. Cell 75:487493[Medline]
-
Shiozaki K, Russell P 1995 Cell-cycle control linked to
extracellular environment by MAP kinase pathway in fission yeast.
Nature 37:739743
-
Aicher B, Lerch MM, Muller T, Schilling J, Ullrich A 1997 Cellular redistribution of protein tyrosine phosphatases LAR and
PTP
by inducible proteolytic processing. J Cell Biol 138:681696[Free Full Text]
-
Uchida T, Matozaki T, Noguchi T, Yamao T, Horita K, Suzuki T,
Fujioka Y, Sakamoto C, Kasuga M 1994 Insulin stimulates the
phosphorylation of Tyr538 and the catalytic activity of PTP1C, a
protein tyrosine phosphatase with Src homology-2 domains. J Biol
Chem 269:1222012228[Abstract/Free Full Text]
-
Lammers R, Moller NP, Ullrich A 1998 Mutant forms of the
protein tyrosine phosphatase
show differential activities towards
intracellular substrates. Biochem Biophys Res Commun 242:3238[CrossRef][Medline]
-
Bandyopadhyay D, Kusari A, Kenner KA, Liu F, Chernoff J,
Gustafson TA, Kusari J 1997 Protein-tyrosine phosphatase 1B complexes
with the insulin receptor in vivo and is
tyrosine-phosphorylated in the presence of insulin. J Biol Chem 272:16391645[Abstract/Free Full Text]
-
Su J, Batzer A, Sap J 1994 Receptor tyrosine phosphatase
R-PTP-
is tyrosine-phosphorylated and associated with the adaptor
protein Grb2. J Biol Chem 269:1873118734[Abstract/Free Full Text]
-
Takebe Y, Seiki M, Fujisawa J, Hoy P, Yokota K, Arai K,
Yoshida M, Arai N 1988 SR
promoter: an efficient and versatile
mammalian cDNA expression system composed of the simian virus 40 early
promoter and the R-U5 segment of human T-cell leukemia virus type 1
long terminal repeat. Mol Cell Biol 8:466472[Medline]
-
Ausubel FM, Brent R, Kingstone RE, Moore DD, Seidman JG, Smith
JA, Struhl K 1987 Current Protocols in Molecular Biology.
John Wiley and Sons, New York